Bayer Cropscience Financial Statements

Bayer Cropscience (BAYERCROP) reported revenue of ₹53.14B in FY2025 with net income of ₹5.68B. Total assets stood at ₹52.46B and free cash flow was ₹2.21B.

Bayer Cropscience Income Statement

Hover the chart icon for year-over-year change.

FY 2024 – FY 2025

Item	Chart	2024	2025
Revenue		48.92B	53.14B
Cost of Rev. Cost of Revenue		-29.12B	-33.99B
Gross Profit		19.81B	19.15B
SGA Sales, General & Admin		-4.35B	-4.50B
Op. Income Operating Income		8.80B	6.05B
PBT Profit Before Tax		9.41B	7.07B
Net Income		7.41B	5.68B
Dil. Shares Diluted Shares		44.94M	44.94M
Diluted EPS		164.77	126.38

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Bayer Cropscience's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Bayer Cropscience Balance Sheet

Hover the chart icon for year-over-year change.

FY 2024 – FY 2025

Item	Chart	2024	2025
Curr. assets Total current assets		39.06B	44.72B
Non-curr. assets Total non-current assets		6.92B	7.74B
Total assets		45.97B	52.46B
Curr. liabilities Total current liabilities		15.97B	22.24B
Non-curr. liab. Total non-current liabilities		1.50B	1.72B
Total liabilities		17.48B	23.96B
Total equity		28.49B	28.50B
Total liab. & eq. Total liabilities & equity		45.97B	52.46B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Bayer Cropscience's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Bayer Cropscience Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2024 – FY 2025

Item	Chart	2024	2025
Net Income		9.41B	7.07B
Operating CF Cash flow Operating Activities		9.52B	2.62B
Capex Investments in PPE		-457.00M	-409.00M
Investing CF Cash flow Investing Activities		4.00M	856.00M
Dividend Paid		-6.07B	-5.61B
Financing CF Cash flow Financing Activities		-6.56B	-6.19B
Cash (start) Cash at beginning of period		8.61B	11.57B
Cash (end) Cash at end of period		11.57B	8.85B
FCF Free Cash Flow		9.06B	2.21B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Bayer Cropscience's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025